Morgan Stanley Reiterates Equal-Weight on BioNTech, Maintains $124 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a $124 price target.
June 26, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Matthew Korn reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a $124 price target.
The news of Morgan Stanley reiterating an Equal-Weight rating on BioNTech and maintaining a $124 price target is neutral for the stock price in the short term. The rating suggests that the stock is fairly valued and the price target is unchanged, indicating no significant change in the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100